Merck & Co Inc- 详细介绍、公司背景、业务范围、财务数据以及市场表现

关于 Merck & Co Inc 公司

公司简介

公司代码MRK

公司名称Merck & Co Inc

上市日期Jan 01, 1941

成立日期1970

CEOMr. Robert M. (Rob) Davis

员工数量75000

证券类型Ordinary Share

年结日Jan 01

公司地址2000 Galloping Hill Road

城市KENILWORTH

上市交易所NYSE Consolidated

国家United States of America

邮编07033

电话19087404000

网址https://www.merck.com/

公司代码MRK

上市日期Jan 01, 1941

成立日期1970

公司高管

名称

名称/职务

职务

持股

持股变动

Mr. Robert M. (Rob) Davis

Chairman of the Board, President, Chief Executive Officer

443.60K

+27.35%

Mr. Sanat Chattopadhyay

Executive Vice President and President - Merck Manufacturing Division

185.32K

+17.89%

Dr. Dean Y. Li, M.D., Ph.D.

Executive Vice President, President - Merck Research Laboratories

78.86K

+70.54%

Ms. Caroline Litchfield

Chief Financial Officer, Executive Vice President

74.34K

+46.03%

Mr. Chirfi Guindo

Senior Vice President, Chief Marketing Officer - Human Health

66.61K

+73.22%

Ms. Jennifer L. Zachary

Executive Vice President, General Counsel, Corporate Secretary

53.41K

+90.81%

Mr. Michael A. Klobuchar

Executive Vice President, Chief Strategy Officer

23.22K

+1.98%

Mr. Joseph Edward Romanelli

Senior Vice President, President - MSD International Human Health

20.71K

+5.86%

Ms. Patricia F. Russo

Independent Director

13.14K

--

Mr. Thomas Henry (Tom) Glocer, J.D.

Lead Independent Director

5.09K

--

名称

名称/职务

职务

持股

持股变动

Mr. Robert M. (Rob) Davis

Chairman of the Board, President, Chief Executive Officer

443.60K

+27.35%

Mr. Sanat Chattopadhyay

Executive Vice President and President - Merck Manufacturing Division

185.32K

+17.89%

Dr. Dean Y. Li, M.D., Ph.D.

Executive Vice President, President - Merck Research Laboratories

78.86K

+70.54%

Ms. Caroline Litchfield

Chief Financial Officer, Executive Vice President

74.34K

+46.03%

Mr. Chirfi Guindo

Senior Vice President, Chief Marketing Officer - Human Health

66.61K

+73.22%

Ms. Jennifer L. Zachary

Executive Vice President, General Counsel, Corporate Secretary

53.41K

+90.81%

收入明细

单位: USD更新时间: 3月5日周三

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2021

FY2020

FY2019

业务USD

名称

营收

占比

Oncology-Keytruda

29.48B

45.94%

Vaccines -Gardasil/Gardasil

8.58B

13.37%

Animal Health-Livestock

3.46B

5.39%

Other pharmaceutical

2.51B

3.91%

Vaccines -ProQuad/M-M-R II/Varivax

2.48B

3.87%

Other

17.64B

27.49%

地区USD

名称

营收

占比

United States

32.27B

50.30%

Europe, Middle East and Africa

14.04B

21.88%

China

5.49B

8.56%

Latin America

3.45B

5.39%

Japan

3.28B

5.11%

Other

5.61B

8.75%

业务

地区

业务USD

名称

营收

占比

Oncology-Keytruda

29.48B

45.94%

Vaccines -Gardasil/Gardasil

8.58B

13.37%

Animal Health-Livestock

3.46B

5.39%

Other pharmaceutical

2.51B

3.91%

Vaccines -ProQuad/M-M-R II/Varivax

2.48B

3.87%

Other

17.64B

27.49%

股东统计

更新时间: 2月21日周五

持股股东

股东类型

持股股东

股东统计

占比

The Vanguard Group, Inc.

9.89%

BlackRock Institutional Trust Company, N.A.

5.67%

State Street Global Advisors (US)

4.78%

Wellington Management Company, LLP

3.19%

Geode Capital Management, L.L.C.

2.42%

Other

74.02%

持股股东

股东统计

占比

The Vanguard Group, Inc.

9.89%

BlackRock Institutional Trust Company, N.A.

5.67%

State Street Global Advisors (US)

4.78%

Wellington Management Company, LLP

3.19%

Geode Capital Management, L.L.C.

2.42%

Other

74.02%

股东类型

股东统计

占比

Investment Advisor/Hedge Fund

35.77%

Investment Advisor

31.62%

Research Firm

3.52%

Pension Fund

2.96%

Bank and Trust

2.38%

Hedge Fund

1.52%

Sovereign Wealth Fund

1.48%

Insurance Company

0.69%

Holding Company

0.63%

Other

19.39%

机构持股

更新时间: 2月20日周四

报告期

机构数

持股数

持股占比

持股变动

2025Q1

5259

2.04B

80.80%

+11.95M

2024Q4

5410

2.04B

80.88%

+11.86M

2024Q3

5200

2.01B

79.47%

-7.95M

2024Q2

5181

2.00B

79.28%

-4.85M

2024Q1

5154

1.99B

78.88%

-6.09M

2023Q4

5065

1.99B

78.60%

+584.80K

2023Q3

4871

1.98B

78.17%

-32.03M

2023Q2

4864

2.00B

78.94%

-18.54M

2023Q1

4818

1.99B

78.43%

-16.95M

2022Q4

4785

1.97B

77.94%

-5.23M

股东持股明细

名称

持股数

占比

持股变动

变动比例

公告日期

The Vanguard Group, Inc.

249.98M

9.89%

+1.31M

+0.52%

Dec 31, 2024

BlackRock Institutional Trust Company, N.A.

143.38M

5.67%

+10.26M

+7.70%

Dec 31, 2024

State Street Global Advisors (US)

120.90M

4.78%

+1.88M

+1.58%

Dec 31, 2024

Wellington Management Company, LLP

80.74M

3.19%

+4.93M

+6.50%

Dec 31, 2024

Geode Capital Management, L.L.C.

61.18M

2.42%

+2.02M

+3.42%

Dec 31, 2024

Norges Bank Investment Management (NBIM)

34.97M

1.38%

+1.17M

+3.46%

Dec 31, 2024

Fidelity Management & Research Company LLC

33.57M

1.32%

-11.94M

-26.24%

Dec 31, 2024

BofA Global Research (US)

23.07M

0.91%

-1.38M

-5.65%

Dec 31, 2024

BlackRock Asset Management Ireland Limited

21.21M

0.83%

+1.34M

+6.76%

Dec 31, 2024

Morgan Stanley Smith Barney LLC

20.62M

0.81%

-290.99K

-1.39%

Dec 31, 2024

持股ETF

更新时间: 3月5日周三

机构名称

占比

Future Fund Active ETF

9.91%

Monarch Dividend Plus Index ETF

6.08%

First Trust NASDAQ Pharmaceuticals ETF

5.68%

Health Care Select Sector SPDR Fund

5.01%

VanEck Pharmaceutical ETF

4.79%

ProShares Smart Materials ETF

4.7%

Invesco Pharmaceuticals ETF

4.67%

iShares U.S. Pharmaceuticals ETF

4.57%

Amplify Weight Loss Drug & Treatment ETF

4.55%

Proshares Ultra Health Care

4.53%

Future Fund Active ETF

占比9.91%

Monarch Dividend Plus Index ETF

占比6.08%

First Trust NASDAQ Pharmaceuticals ETF

占比5.68%

Health Care Select Sector SPDR Fund

占比5.01%

VanEck Pharmaceutical ETF

占比4.79%

ProShares Smart Materials ETF

占比4.7%

Invesco Pharmaceuticals ETF

占比4.67%

iShares U.S. Pharmaceuticals ETF

占比4.57%

Amplify Weight Loss Drug & Treatment ETF

占比4.55%

Proshares Ultra Health Care

占比4.53%

分红派息

近5年累计派现 35.12B 美元

公告日期

分红计划

股权登记日

现金发放日

除权除息日

Nov 19, 2024

MRK.NB Final Cash Dividend of gross USD 0.81 paid on Jan 08, 2025 going ex on Dec 16, 2024

Dec 16, 2024

Jan 08, 2025

Dec 16, 2024

Jul 23, 2024

MRK.NB Interim Cash Dividend of gross USD 0.77 paid on Oct 07, 2024 going ex on Sep 16, 2024

Sep 16, 2024

Oct 07, 2024

Sep 16, 2024

May 29, 2024

MRK.NB Interim Cash Dividend of gross USD 0.77 paid on Jul 08, 2024 going ex on Jun 17, 2024

Jun 17, 2024

Jul 08, 2024

Jun 17, 2024

Jan 23, 2024

MRK.NB Interim Cash Dividend of gross USD 0.77 paid on Apr 05, 2024 going ex on Mar 14, 2024

Mar 15, 2024

Apr 05, 2024

Mar 14, 2024

Nov 28, 2023

MRK.NB Final Cash Dividend of gross USD 0.77 paid on Jan 08, 2024 going ex on Dec 14, 2023

Dec 15, 2023

Jan 08, 2024

Dec 14, 2023

Jul 25, 2023

MRK.NB Interim Cash Dividend of gross USD 0.73 paid on Oct 06, 2023 going ex on Sep 14, 2023

Sep 15, 2023

Oct 06, 2023

Sep 14, 2023

May 23, 2023

MRK.NB Interim Cash Dividend of gross USD 0.73 paid on Jul 10, 2023 going ex on Jun 14, 2023

Jun 15, 2023

Jul 10, 2023

Jun 14, 2023

Jan 24, 2023

MRK.NB Interim Cash Dividend of gross USD 0.73 paid on Apr 10, 2023 going ex on Mar 14, 2023

Mar 15, 2023

Apr 10, 2023

Mar 14, 2023

Nov 30, 2022

MRK.NB Final Cash Dividend of gross USD 0.73 paid on Jan 09, 2023 going ex on Dec 14, 2022

Dec 15, 2022

Jan 09, 2023

Dec 14, 2022

Jul 26, 2022

MRK.NB Interim Cash Dividend of gross USD 0.69 paid on Oct 07, 2022 going ex on Sep 14, 2022

Sep 15, 2022

Oct 07, 2022

Sep 14, 2022

拆合股

公告日期

类型

比率

暂无数据

公告日期

类型

比率

暂无数据

Merck & Co Inc

92.720USD

Merck & Co Inc

92.720

概览

公司